Slieker Martijn G, Sanders Elisabeth A M, Rijkers Ger T, Ruven Henk J T, van der Ent Cornelis K
Cystic Fibrosis Center Utrecht, University Medical Center Utrecht, P.O. Box 85090, 3508AB Utrecht, The Netherlands.
J Cyst Fibros. 2005 Aug;4 Suppl 2:7-13. doi: 10.1016/j.jcf.2005.05.006.
The variation in cystic fibrosis (CF) lung disease and development of CF related complications correlates poorly with the genotype of the CF transmembrane regulator (CFTR) and with environmental factors. Increasing evidence suggests that phenotypic variation in CF can be attributed to genetic variation in genes other than the CFTR gene, so-called modifier genes. In recent years, multiple candidate modifier genes have been investigated in CF, especially genes that are involved in the control of infection, immunity and inflammation. Some of these genes have been rather conclusively identified as modifiers of the CF phenotype, whereas associations found in other genes have not been confirmed or are conflicting. Identification of genetic variation in modifier genes, obtained by genotype-phenotype studies in well-defined patient populations, may be used as an aid to prognosis and may provide the possibility of new therapeutic interventions.
囊性纤维化(CF)肺部疾病的变异以及CF相关并发症的发生与CF跨膜传导调节因子(CFTR)的基因型和环境因素的相关性较差。越来越多的证据表明,CF的表型变异可归因于CFTR基因以外的其他基因的遗传变异,即所谓的修饰基因。近年来,在CF中对多个候选修饰基因进行了研究,尤其是那些参与感染、免疫和炎症控制的基因。其中一些基因已被相当确凿地确定为CF表型的修饰因子,而在其他基因中发现的关联尚未得到证实或相互矛盾。通过在明确界定的患者群体中进行基因型-表型研究获得的修饰基因遗传变异的鉴定,可用于辅助预后,并可能提供新的治疗干预可能性。